Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil

Detalhes bibliográficos
Autor(a) principal: Silva-Pinto,Ana Cristina
Data de Publicação: 2013
Outros Autores: Angulo,Ivan Lucena, Brunetta,Denise Menezes, Neves,Fabia Idalina Rodrigues, Bassi,Sarah Cristina, Santis,Gil Cunha De, Covas,Dimas Tadeu
Tipo de documento: Artigo
Idioma: eng
Título da fonte: São Paulo medical journal (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802013000400238
Resumo: CONTEXT AND OBJECTIVES Sickle cell disease (SCD) is the most common genetic disorder among people of African descent, affecting approximately 3,500 newborns each year in Brazil. Hydroxyurea (HU) is the only effective drug to treating patients with SCD, thereby reducing morbidity and mortality. The objective was to analyze the effects of HU on SCD patients at our institution. DESIGN AND SETTING Retrospective study conducted at a sickle cell centre in Ribeirão Preto, São Paulo, Brazil. METHODS We analyzed clinical and laboratory data on 37 patients. The hematological parameters and clinical events that occurred during the year before and the first year of treatment with HU were analyzed. The mean dose of HU was 24.5 ± 5.5 mg/kg/day. RESULTS There were rises in three parameters: hemoglobin (8.3 g/dl to 9.0 g/dl, P = 0.0003), fetal hemoglobin (HbF) (2.6% to 19.8%, P < 0.0001) and mean cell volume MCV (89 to 105 fl, P = 0.001); and reductions in the numbers of leukocytes (10,050/µl to 5,700/µl, P < 0.0001), neutrophils (6,200/µl to 3,400/µl, P = 0.001), platelets (459,000/µl to 373,000/µl, P = 0.0002), painful crises (1.86 to 0.81, P = 0.0014), acute chest syndromes (0.35 to 0.08, P = 0.0045), infections (1.03 to 0.5, P = 0.047), hospitalizations (1.63 to 0.53, P = 0.0013) and transfusions (1.23 to 0.1, P = 0.0051). CONCLUSION The patients presented clinical and hematological improvements, with an increase in HbF and a reduction in the infection rate, which had not been addressed in most previous studies.
id APM-1_feaeb698b594013db63931696e4fd47f
oai_identifier_str oai:scielo:S1516-31802013000400238
network_acronym_str APM-1
network_name_str São Paulo medical journal (Online)
repository_id_str
spelling Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in BrazilAnemia, sickle cellHydroxyureaFetal hemoglobinAcute chest syndromeErythrocyte indices CONTEXT AND OBJECTIVES Sickle cell disease (SCD) is the most common genetic disorder among people of African descent, affecting approximately 3,500 newborns each year in Brazil. Hydroxyurea (HU) is the only effective drug to treating patients with SCD, thereby reducing morbidity and mortality. The objective was to analyze the effects of HU on SCD patients at our institution. DESIGN AND SETTING Retrospective study conducted at a sickle cell centre in Ribeirão Preto, São Paulo, Brazil. METHODS We analyzed clinical and laboratory data on 37 patients. The hematological parameters and clinical events that occurred during the year before and the first year of treatment with HU were analyzed. The mean dose of HU was 24.5 ± 5.5 mg/kg/day. RESULTS There were rises in three parameters: hemoglobin (8.3 g/dl to 9.0 g/dl, P = 0.0003), fetal hemoglobin (HbF) (2.6% to 19.8%, P < 0.0001) and mean cell volume MCV (89 to 105 fl, P = 0.001); and reductions in the numbers of leukocytes (10,050/µl to 5,700/µl, P < 0.0001), neutrophils (6,200/µl to 3,400/µl, P = 0.001), platelets (459,000/µl to 373,000/µl, P = 0.0002), painful crises (1.86 to 0.81, P = 0.0014), acute chest syndromes (0.35 to 0.08, P = 0.0045), infections (1.03 to 0.5, P = 0.047), hospitalizations (1.63 to 0.53, P = 0.0013) and transfusions (1.23 to 0.1, P = 0.0051). CONCLUSION The patients presented clinical and hematological improvements, with an increase in HbF and a reduction in the infection rate, which had not been addressed in most previous studies. Associação Paulista de Medicina - APM2013-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802013000400238Sao Paulo Medical Journal v.131 n.4 2013reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/1516-3180.2013.1314467info:eu-repo/semantics/openAccessSilva-Pinto,Ana CristinaAngulo,Ivan LucenaBrunetta,Denise MenezesNeves,Fabia Idalina RodriguesBassi,Sarah CristinaSantis,Gil Cunha DeCovas,Dimas Tadeueng2013-11-19T00:00:00Zoai:scielo:S1516-31802013000400238Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2013-11-19T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse
dc.title.none.fl_str_mv Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil
title Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil
spellingShingle Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil
Silva-Pinto,Ana Cristina
Anemia, sickle cell
Hydroxyurea
Fetal hemoglobin
Acute chest syndrome
Erythrocyte indices
title_short Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil
title_full Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil
title_fullStr Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil
title_full_unstemmed Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil
title_sort Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil
author Silva-Pinto,Ana Cristina
author_facet Silva-Pinto,Ana Cristina
Angulo,Ivan Lucena
Brunetta,Denise Menezes
Neves,Fabia Idalina Rodrigues
Bassi,Sarah Cristina
Santis,Gil Cunha De
Covas,Dimas Tadeu
author_role author
author2 Angulo,Ivan Lucena
Brunetta,Denise Menezes
Neves,Fabia Idalina Rodrigues
Bassi,Sarah Cristina
Santis,Gil Cunha De
Covas,Dimas Tadeu
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva-Pinto,Ana Cristina
Angulo,Ivan Lucena
Brunetta,Denise Menezes
Neves,Fabia Idalina Rodrigues
Bassi,Sarah Cristina
Santis,Gil Cunha De
Covas,Dimas Tadeu
dc.subject.por.fl_str_mv Anemia, sickle cell
Hydroxyurea
Fetal hemoglobin
Acute chest syndrome
Erythrocyte indices
topic Anemia, sickle cell
Hydroxyurea
Fetal hemoglobin
Acute chest syndrome
Erythrocyte indices
description CONTEXT AND OBJECTIVES Sickle cell disease (SCD) is the most common genetic disorder among people of African descent, affecting approximately 3,500 newborns each year in Brazil. Hydroxyurea (HU) is the only effective drug to treating patients with SCD, thereby reducing morbidity and mortality. The objective was to analyze the effects of HU on SCD patients at our institution. DESIGN AND SETTING Retrospective study conducted at a sickle cell centre in Ribeirão Preto, São Paulo, Brazil. METHODS We analyzed clinical and laboratory data on 37 patients. The hematological parameters and clinical events that occurred during the year before and the first year of treatment with HU were analyzed. The mean dose of HU was 24.5 ± 5.5 mg/kg/day. RESULTS There were rises in three parameters: hemoglobin (8.3 g/dl to 9.0 g/dl, P = 0.0003), fetal hemoglobin (HbF) (2.6% to 19.8%, P < 0.0001) and mean cell volume MCV (89 to 105 fl, P = 0.001); and reductions in the numbers of leukocytes (10,050/µl to 5,700/µl, P < 0.0001), neutrophils (6,200/µl to 3,400/µl, P = 0.001), platelets (459,000/µl to 373,000/µl, P = 0.0002), painful crises (1.86 to 0.81, P = 0.0014), acute chest syndromes (0.35 to 0.08, P = 0.0045), infections (1.03 to 0.5, P = 0.047), hospitalizations (1.63 to 0.53, P = 0.0013) and transfusions (1.23 to 0.1, P = 0.0051). CONCLUSION The patients presented clinical and hematological improvements, with an increase in HbF and a reduction in the infection rate, which had not been addressed in most previous studies.
publishDate 2013
dc.date.none.fl_str_mv 2013-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802013000400238
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802013000400238
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1516-3180.2013.1314467
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Paulista de Medicina - APM
publisher.none.fl_str_mv Associação Paulista de Medicina - APM
dc.source.none.fl_str_mv Sao Paulo Medical Journal v.131 n.4 2013
reponame:São Paulo medical journal (Online)
instname:Associação Paulista de Medicina
instacron:APM
instname_str Associação Paulista de Medicina
instacron_str APM
institution APM
reponame_str São Paulo medical journal (Online)
collection São Paulo medical journal (Online)
repository.name.fl_str_mv São Paulo medical journal (Online) - Associação Paulista de Medicina
repository.mail.fl_str_mv revistas@apm.org.br
_version_ 1754209263529492480